Muhammad Zia Khan1, Salman Zahid2, Muhammad U Khan3, Asim Kichloo4, Shakeel Jamal4, Abdul Mannan Khan Minhas5, Muhammad Bilal Munir6, Sudarshan Balla3. 1. Department of Medicine, West Virginia University, Morgantown, West Virginia, USA. 2. Department of Medicine, Rochester General Hospital, Rochester, New York, USA. 3. Division of Cardiovascular Medicine, West Virginia University Heart and Vascular Institute, Morgantown, West Virginia, USA. 4. Department of Medicine, St. Mary's of Saginaw Hospital, Saginaw, Michigan, USA. 5. Department of Medicine, Forrest General Hospital, Hattiesburg, Mississippi, USA. 6. Division of Cardiovascular Medicine, University of California San Diego, La Jolla, California, USA.
Abstract
OBJECTIVES: To study trends of utilization, outcomes, and cost of care in patients undergoing undergoing transcatheter mitral valve repair (TMVr) with end-stage renal disease (ESRD). BACKGROUND: Renal disease has been known to be a predictor of poor outcome in patients with mitral valve disease. Outcome data for patients with ESRD undergoing TMVr remains limited. Therefore, our study aims to investigate trends of utilization, outcomes, and cost of care among patients with ESRD undergoing TMVr. METHODS: We analyzed NIS data from January 2010 to December 2017 using the ICD-9-CM codes ICD-10-CM to identify patients who underwent TMVr. Baseline characteristics were compared using a Pearson 𝜒2 test for categorical variables and independent samples t-test for continuous variables. Propensity matched analysis was done for adjusted analysis to compare outcomes between TMVr with and without ESRD. Markov chain Monte Carlo was used to account for missing values. RESULTS: A total of 15,260 patients (weighted sample) undergoing TMVr were identified between 2010 and 2017. Of these, 638 patients had ESRD compared to 14,631 patients who did not have ESRD. Adjusted in-hospital mortality was lower in non-ESRD group (3.9 vs. <1.8%). Similarly, ESRD patients were more likely to have non-home discharges (85.6 vs. 74.9%). ESRD patients also had a longer mean length of stay (7.9 vs. 13.5 days) and higher mean cost of stay ($306,300 vs. $271,503). CONCLUSION: ESRD is associated with higher mortality, complications, and resource utilization compared to non-ESRD patients. It is important to include this data in shared decision-making process and patient selection.
OBJECTIVES: To study trends of utilization, outcomes, and cost of care in patients undergoing undergoing transcatheter mitral valve repair (TMVr) with end-stage renal disease (ESRD). BACKGROUND: Renal disease has been known to be a predictor of poor outcome in patients with mitral valve disease. Outcome data for patients with ESRD undergoing TMVr remains limited. Therefore, our study aims to investigate trends of utilization, outcomes, and cost of care among patients with ESRD undergoing TMVr. METHODS: We analyzed NIS data from January 2010 to December 2017 using the ICD-9-CM codes ICD-10-CM to identify patients who underwent TMVr. Baseline characteristics were compared using a Pearson 𝜒2 test for categorical variables and independent samples t-test for continuous variables. Propensity matched analysis was done for adjusted analysis to compare outcomes between TMVr with and without ESRD. Markov chain Monte Carlo was used to account for missing values. RESULTS: A total of 15,260 patients (weighted sample) undergoing TMVr were identified between 2010 and 2017. Of these, 638 patients had ESRD compared to 14,631 patients who did not have ESRD. Adjusted in-hospital mortality was lower in non-ESRD group (3.9 vs. <1.8%). Similarly, ESRD patients were more likely to have non-home discharges (85.6 vs. 74.9%). ESRD patients also had a longer mean length of stay (7.9 vs. 13.5 days) and higher mean cost of stay ($306,300 vs. $271,503). CONCLUSION: ESRD is associated with higher mortality, complications, and resource utilization compared to non-ESRD patients. It is important to include this data in shared decision-making process and patient selection.
Authors: Divyanshu Mohananey; Brian P Griffin; Lars G Svensson; Zoran B Popovic; E Murat Tuzcu; L Leonardo Rodriguez; Samir R Kapadia; Milind Y Desai Journal: Circ Cardiovasc Interv Date: 2017-10 Impact factor: 6.546
Authors: Rick A Nishimura; Catherine M Otto; Robert O Bonow; Blase A Carabello; John P Erwin; Robert A Guyton; Patrick T O'Gara; Carlos E Ruiz; Nikolaos J Skubas; Paul Sorajja; Thoralf M Sundt; James D Thomas Journal: J Am Coll Cardiol Date: 2014-03-03 Impact factor: 24.094
Authors: Francesco Maisano; Olaf Franzen; Stephan Baldus; Ulrich Schäfer; Jörg Hausleiter; Christian Butter; Gian Paolo Ussia; Horst Sievert; Gert Richardt; Julian D Widder; Tiziano Moccetti; Wolfgang Schillinger Journal: J Am Coll Cardiol Date: 2013-06-07 Impact factor: 24.094
Authors: Mariana Mirabel; Bernard Iung; Gabriel Baron; David Messika-Zeitoun; Delphine Détaint; Jean-Louis Vanoverschelde; Eric G Butchart; Philippe Ravaud; Alec Vahanian Journal: Eur Heart J Date: 2007-03-09 Impact factor: 29.983
Authors: Vinod H Thourani; William S Weintraub; Robert A Guyton; Ellis L Jones; Willis H Williams; Sharif Elkabbani; Joseph M Craver Journal: Circulation Date: 2003-06-30 Impact factor: 29.690
Authors: Gregg W Stone; JoAnn Lindenfeld; William T Abraham; Saibal Kar; D Scott Lim; Jacob M Mishell; Brian Whisenant; Paul A Grayburn; Michael Rinaldi; Samir R Kapadia; Vivek Rajagopal; Ian J Sarembock; Andreas Brieke; Steven O Marx; David J Cohen; Neil J Weissman; Michael J Mack Journal: N Engl J Med Date: 2018-09-23 Impact factor: 91.245